These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9345415)

  • 21. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system.
    Hedlund G; Link H; Zhu J; Xiao BG
    Int Immunopharmacol; 2001 Jun; 1(6):1123-30. PubMed ID: 11407306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
    Murray TJ
    Curr Med Res Opin; 2004 Jan; 20(1):25-30. PubMed ID: 14741068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and treatment of type I diabetes in NOD mice by linomide.
    Slavin S; Gross D; Weiss L
    Transplant Proc; 1995 Dec; 27(6):3240. PubMed ID: 8539933
    [No Abstract]   [Full Text] [Related]  

  • 25. Experimental allergic encephalomyelitis as a guide to the understanding and treatment of multiple sclerosis.
    Whitaker JN; Mitchell GW
    Ann Neurol; 1993 Nov; 34(5):636-7. PubMed ID: 8239557
    [No Abstract]   [Full Text] [Related]  

  • 26. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
    Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
    Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
    Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Ben-Nun A; Kalland T; Abramsky O
    Ann Neurol; 1993 Nov; 34(5):654-60. PubMed ID: 8239559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiformic modulation of endotoxin effects by linomide.
    Shalev M; Ko A; Gelderman MP; Fortin E; Reed G; Slavin S; Gery I
    Clin Immunol; 1999 Dec; 93(3):250-5. PubMed ID: 10600336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving combination trials for multiple sclerosis.
    Trojano M
    Lancet Neurol; 2010 Jul; 9(7):646-7. PubMed ID: 20542737
    [No Abstract]   [Full Text] [Related]  

  • 32. [Beta interferon in multiple sclerosis: pharmacological differences].
    Allain H; Bentué-Ferrer D; Schück S; Ruffault A
    Rev Neurol (Paris); 1999; 155 Suppl 2():S24-30. PubMed ID: 10367322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
    Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Still no evidence on the efficacy of immunomodulatory therapy in reducing functional impairment in multiple sclerosis].
    Vermeulen M
    Ned Tijdschr Geneeskd; 2007 Apr; 151(15):850-1. PubMed ID: 17472114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of phlogenzym in long-term treatment of patients with multiple sclerosis].
    Mialovyts'ka OA
    Lik Sprava; 2003; (3-4):109-13. PubMed ID: 12889375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Interferon beta-1a (Avonex TM): clinical and MRI impacts].
    Vermersch P
    Rev Neurol (Paris); 1999; 155 Suppl 2():S13-9. PubMed ID: 10367320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras).
    Rapoport MJ; Weiss L; Mor A; Bistritzer T; Ramot Y; Slavin S
    J Immunol; 1996 Nov; 157(10):4721-5. PubMed ID: 8906854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 39. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linomide, a novel immunomodulator that prevents death in four models of septic shock.
    Gonzalo JA; González-García A; Kalland T; Hedlund G; Martínez C; Kroemer G
    Eur J Immunol; 1993 Sep; 23(9):2372-4. PubMed ID: 8370414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.